These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 21618503)
1. Cancer immunotherapy: Progress and challenges in the clinical setting. Zarour HM; Ferrone S Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503 [No Abstract] [Full Text] [Related]
2. Cocktails for cancer with a measure of immunotherapy. Ledford H Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078 [No Abstract] [Full Text] [Related]
3. Breakthrough of the year 2013. Cancer immunotherapy. Couzin-Frankel J Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284 [No Abstract] [Full Text] [Related]
4. The struggle to do no harm in clinical trials. Schmidt C Nature; 2017 Dec; 552(7685):S74-S75. PubMed ID: 29293235 [No Abstract] [Full Text] [Related]
5. Cancer immunotherapy. Bender E Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244 [No Abstract] [Full Text] [Related]
6. Cancer Immunotherapy: Theory and Application. Chen G; Bodogai M; Tamehiro N; Shen C; Dou J J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133 [No Abstract] [Full Text] [Related]
7. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Tran E; Robbins PF; Rosenberg SA Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830 [TBL] [Abstract][Full Text] [Related]
8. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Furness AJ; Quezada SA; Peggs KS Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975 [No Abstract] [Full Text] [Related]
12. Human Tumor Antigens and Cancer Immunotherapy. Vigneron N Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423 [TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
15. Future of immunotherapy drug combinations and biomarkers. Schmidt C J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694 [No Abstract] [Full Text] [Related]
16. The benefits of immunotherapy combinations. Schmidt C Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245 [No Abstract] [Full Text] [Related]
17. Future directions in bladder cancer immunotherapy: towards adaptive immunity. Smith SG; Zaharoff DA Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539 [TBL] [Abstract][Full Text] [Related]
18. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Peinert S; Kershaw MH; Prince HM Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906 [No Abstract] [Full Text] [Related]